Acton Pharmaceuticals raises $14M funding round

Acton Pharmaceuticals Inc., a respiratory therapeutics firm in Marlborough, has raised $14.2 million from an offering of Series A-1 convertible preferred stock, according to a regulatory filing with the U.S. Securities and Exchange Commission.

Although the filing does not identify the two investors in the financing, it does list Sequoia Capital partner Scott Carter, who sits on the Acton Pharmaceuticals board of directors, as a related person in the financing.